Product Description
E7130 is a next-generation agent improving tumor microenvironment, which has been developed by a joint research with Eisai and Harvard University. E7130 is derived from total synthesis of halichondrin, a natural product isolated from the marine sponge Halichondria okadai. E7130 is believed to improve tumor microenvironment by unique action for potential effect on immune activation by releasing hypoxia and suppressing interaction between cancer cells and stroma. (Sourced from: https://www.eisai.com/news/2019/news201943.html)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Head and Neck Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| E7130-J081-101 | P1 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma |
2026-06-30 |